Tenovin-1 pretreatment enhances HCC cell resistance to doxorubicin following co-treatment with an miR-26b mimic, indicating that the USP9X/p53/ubiquitination/degradation pathway is important for miR-26b-mediated chemotherapy sensitivity. The gene discussed is TP53; the disease is hepatocellular carcinoma.